Nuveen LLC Acquires New Holdings in TransMedics Group, Inc. $TMDX

Key Points

• Nuveen LLC acquired a new stake in TransMedics Group, Inc. by purchasing 88,096 shares valued at approximately $5.9 million, representing about 0.26% ownership in the company.
• TransMedics reported a strong quarterly performance with $0.92 EPS, exceeding expectations, and a revenue increase of 37.7% year-over-year, totaling $157.37 million.
• Analysts are optimistic about TransMedics, with several rating upgrades; the consensus target price has increased to $123.00, suggesting potential for growth in the stock.

Nuveen LLC acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 88,096 shares of the company's stock, valued at approximately $5,927,000. Nuveen LLC owned approximately 0.26% of TransMedics Group at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of TMDX. Braidwell LP purchased a new position in TransMedics Group in the 4th quarter valued at $57,493,000. Mackenzie Financial Corp raised its stake in shares of TransMedics Group by 73.0% during the 4th quarter. Mackenzie Financial Corp now owns 828,147 shares of the company's stock worth $51,635,000 after buying an additional 349,403 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of TransMedics Group by 1,565.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock worth $16,820,000 after buying an additional 253,624 shares during the last quarter. Avidity Partners Management LP raised its stake in TransMedics Group by 597.1% in the 4th quarter. Avidity Partners Management LP now owns 192,400 shares of the company's stock valued at $11,996,000 after purchasing an additional 164,800 shares during the last quarter. Finally, Frontier Capital Management Co. LLC acquired a new position in TransMedics Group in the 4th quarter valued at about $9,415,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the sale, the insider directly owned 13,955 shares of the company's stock, valued at $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.00% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of research analyst reports. Morgan Stanley upped their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Monday. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Oppenheimer upped their price objective on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Finally, Canaccord Genuity Group upped their price objective on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $123.00.

TransMedics Group Stock Down 1.5%

NASDAQ TMDX traded down $1.76 on Friday, reaching $114.96. The company had a trading volume of 665,572 shares, compared to its average volume of 1,310,928. The firm has a market capitalization of $3.92 billion, a PE ratio of 59.57 and a beta of 2.09. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $172.78. The firm has a 50-day moving average of $120.41 and a 200-day moving average of $102.52. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. The business had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The business's revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.